Gastric Helicobacter pylori infection is the main cause of peptic ulcers and gastric cancer. Remarkably, an estimated 80-90% of the adults in low and middle-income countries are infected with H. pylori. An estimated 10-15% of the infected individuals will develop peptic ulcer disease and 1-2% gastric cancer. Antibiotic treatment can cure peptic ulcer disease but reinfection is common. From a public health perspective, a vaccine against H. pylori will reduce the consumption of antibiotics, the incidence of associated symptoms and rate of reinfections. The main target group for such a vaccine would be adults in low and middle-income countries where H. pylori infection is endemic. Our group at the University of Gothenburg (UG) has been working for the last 20 years on the development of a mucosally delivered vaccine against H. pylori infection. Based on the results from our pre-clinical studies, a vaccine candidate will be chosen to advance to Phase I clinical trials in H. pylori infected adults and later in children in close collaboration with an industrial partner. The vaccine will be scaled up for production under GMP conditions. Pre-vaccine specific immune responses in H. pylori infected individuals in India will be studied and a Phase I trial will be carried out in India. Considering the previous experience at UG in developing mucosal vaccines, we are optimistic that we could develop an effective and low-cost H. pylori vaccine under the framework of this application.. This project was identified by RTI International for their own research purposes and some fields do not align with The GO Map categories. End dates were estimated as one year after the start date. The Project Type "Research, Clinical" may not accurately describe this project's focus but was used for all RTI International's Global Noncommunicable Diseases Initiative projects added in June 2018. Specialties were not analyzed. All project funding was valued in 2015 USD.